GenVec Receives Grant for RSV Vaccine Program
Posted on: Wednesday, 7 May 2008, 12:01 CDT
GenVec has received an advanced technology Phase I Small Business Innovation and Research grant from the National Institute of Allergy and Infectious Diseases, of the National Institutes of Health, to support the company's efforts to develop vaccines for the prevention of respiratory syncytial virus.
The SBIR grant, valued at $600,000 over two years, will support work being conducted exclusively at GenVec.
Rick King, senior vice president of research at GenVec, said: "The overall goal of this program is to develop a safe vaccine that provides protection against respiratory syncytial virus (RSV). RSV has long been recognized as a priority target for vaccine development and our program has the potential to address this significant unmet medical need."
Source: Datamonitor
Related Articles
- GenVec to Present at the Fourth Annual Needham & Company Biotechnology Conference
- GenVec Reports First Quarter 2005 Financial Results
- GenVec Reports Preclinical Research at AACR Showing TNFerade Effective Against Metastases in Melanoma Model and Demonstrating Targeting in Ovarian Cancer Model
- GenVec Launches Phase IIB Trial in Patients With Severe Coronary Artery Disease
- MD-Based GenVec Says Baltimore Eye Institute Participating in Drug Trial
- Article Says MD-Based GenVec Developed Gene That May Improve Hearing in Deaf Guinea Pigs
- GenVec: Getting the Green Light
- GenVec Receives FDA Clearance to Proceed With the Randomized Portion of the Phase II Clinical Study of TNFerade(TM) in Pancreatic Cancer
- National Institute of Health Supports MD-Based GenVec With $10M
- Gaithersburg-Based GenVec Obtains License From National Institutes of Health
 |
 |
User Comments (0)
RSS Feeds